PLCL 70:30 | LCL705

PLCL 70:30 | LCL705, Poly(L-lactide-co-ε-caprolactone) | is an Ester terminated Medical Grade copolymer of L-lactide and ε-caprolactone with an inherent viscosity midpoint of 1.2 dl/g. Biodegradable, biocompatible, and bioresorbable copolymer composed of L-Lactide and ε-Caprolactone. This semi-crystalline material has been used in the fabrication of research medical devices and research tissue engineering solutions, such as orthopedic or soft tissue fixation devices. Degradation of these materials has been thoroughly studied and has been shown to be safely resorbed by the body after implantation. Modification of molecular weight and polymer composition allows for control of the degradation rate and mechanical stability of the polymer.

CAS Number:

Manufacturing Process:

Molecular Formula:

Get Quote

Additional information


(3S-cis)-3, 4-Dioxane-2, 5-dione copolymer, 6-dimethyl-1, PLCL, polymer with 2-oxepanone

Substance Type

Biodegradable Polymer, Excipient, Nanoparticles, Non-Active pharmaceutical ingredient, PLCL 70:30, Inherent Viscosity: 0.90 – 1.20 dL/g

EPA Registry Name

L-lactide/Caprolactone copolymer



Lactide by NMR

ε-caprolactone by NMR

Viscosity (0.5% in CHCl3 at 30°C)

Residual monomer L-Lactide

Residual monomer ε-caprolactone

Residual solvent acetone

Residual solvent toluene

Heavy metal


Sulphated Ash



Bacterial Endotoxins

Molecular Weight

~120,000 da

Inhalable dry powder containing lipid polymer hybrid nanoparticles of Nintedanib esylate: In vitro and in vivo evaluations

Abstract: The key objective of this research work was to develop and evaluate dry powder for inhalation containing lipid polymer... Read More


Abstract: The aim of the present study was to develop, optimize, and evaluate methotrexate containing poloxamer 407 coated polymeric nanoparticles... Read More

Human beta defensin-2 loaded PLGA nanoparticles impregnated in collagen-chitosan composite scaffold for the management of diabetic wounds

Abstract Diabetic wound (DW) is the most devastating complication resulting in significant mortality and morbidity in diabetic patients. The standard... Read More

Formulation and Evaluation of Pralidoxime-PLGA Microspheres as Antidote against Organophosphorus Poisioning

Abstract Objective: The objective of the present work is to formulate and evaluate Pralidoxime chloride (PAM)-controlled release microspheres using poly... Read More

A tailored solution for localized drug delivery in liver cancer treatment

ABSTRACT Adjuvant chemotherapy is highly recommended for liver cancer to enhance survival rates due to its tendency to recur frequently.... Read More

**Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs): a reliable drug delivery system for the treatment of glioblastoma

Polymeric lipid hybrid nanoparticles (PHLNPs) are core-shell nanoparticle structures made up of polymer cores and lipid shells that have properties similar to both polymeric nanoparticles and liposomes. Methotrexate (MTX) loaded PLHNPs containing tween 80, phosphatidylcholine, poly D,... Read More

**Statistically designed vitamin D3 Encapsulated PLGA **microspheres dispersed in thermoresponsive in-situ gel for nasal delivery

Vitamin D deficiency is a cause of concern across the world. It is a fat-soluble vitamin and exhibits two molecular forms (D2 and D3). The aim of the present study is the development and optimization of vitamin D3 loaded PLGA microspheres by using Box Behnken Design. Additionally, to enhance nasal... Read More

**Evaluating the osteogenic potential of insulin-like growth factor-1 microspheres on osteoblastic activity around dental implants in patients with type 2 diabetes mellitus using bone scintigraphy: A split-mouth randomized controlled trial

Dental implants are susceptible to early failure when placed in patients diagnosed with type 2 diabetes mellitus. The osteoinductive potential of insulin-like growth factor-1 (IGF-1) has been widely investigated in animals with type 2 diabetes mellitus, but studies investigating the osteoinductive... Read More

Get Quote for PLCL 70:30 | LCL705